Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1987 Nov 7;295(6607):1165–1168. doi: 10.1136/bmj.295.6607.1165

Cyclosporin treatment of IgA nephropathy: a short term controlled trial.

K N Lai 1, F M Lai 1, P K Li 1, J Vallance-Owen 1
PMCID: PMC1248243  PMID: 3120928

Abstract

Cyclosporin's known regulatory effects on the immune system suggest that it may be useful in treating patients with IgA nephropathy. A randomised prospective single blind study of 19 patients with IgA nephropathy and proteinuria (greater than 1.5 g/day) was conducted to determine the therapeutic value of cyclosporin. The patients were divided into two groups: nine patients were given oral cyclosporin (5 mg/kg/day) for 12 weeks and 10 patients a placebo. The two groups were comparable in age of presentation, ratio of men to women, plasma creatinine and serum IgA concentrations, creatinine clearance, daily urinary protein excretion, severity of renal histopathological changes, and prevalence of hypertension. A significant reduction of proteinuria and an increase of plasma albumin concentration was observed with treatment with cyclosporin. Nevertheless, a significant rise of plasma creatinine concentration and a fall in creatinine clearance was found in patients after six weeks' treatment with cyclosporin, although the plasma cyclosporin concentrations were maintained within a narrow therapeutic range. Serum IgA concentrations were reduced in seven patients. Renal function improved within eight weeks after treatment was stopped. Three months after treatment was stopped proteinuria remained less than half of the pretreatment values in three patients. No similar biochemical changes were observed in the controls. Short term cyclosporin therapy may be beneficial in reducing proteinuria in some patients with IgA nephropathy. As transient renal impairment was seen, despite cyclosporin concentrations being maintained within a narrow therapeutic range, indiscriminate use of cyclosporin in glomerulonephritis should be discouraged.

Full text

PDF
1165

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. D'Amico G., Imbasciati E., Barbiano Di Belgioioso G., Bertoli S., Fogazzi G., Ferrario F., Fellin G., Ragni A., Colasanti G., Minetti L. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine (Baltimore) 1985 Jan;64(1):49–60. [PubMed] [Google Scholar]
  2. Egido J., Blasco R., Sancho J., Lozano L. T-cell dysfunctions in IgA nephropathy: specific abnormalities in the regulation of IgA synthesis. Clin Immunol Immunopathol. 1983 Feb;26(2):201–212. doi: 10.1016/0090-1229(83)90138-1. [DOI] [PubMed] [Google Scholar]
  3. Egido J., Rivera F., Sancho J., Barat A., Hernando L. Phenytoin in IgA nephropathy: a long-term controlled trial. Nephron. 1984;38(1):30–39. doi: 10.1159/000183274. [DOI] [PubMed] [Google Scholar]
  4. Gunn H. C., Ryffel B. Glomerulonephritis in NZB/W mice: therapeutic effect of cyclosporine. Clin Nephrol. 1986;25 (Suppl 1):S189–S192. [PubMed] [Google Scholar]
  5. Hale G. M., McIntosh S. L., Hiki Y., Clarkson A. R., Woodroffe A. J. Evidence for IgA-specific B cell hyperactivity in patients with IgA nephropathy. Kidney Int. 1986 Mar;29(3):718–724. doi: 10.1038/ki.1986.57. [DOI] [PubMed] [Google Scholar]
  6. Hess A. D., Tutschka P. J., Pu Z., Santos G. W. Effect of cyclosporin A on human lymphocyte responses in vitro. IV. Production of T cell stimulatory growth factors and development of responsiveness to these growth factors in CsA-treated primary MLR cultures. J Immunol. 1982 Jan;128(1):360–367. [PubMed] [Google Scholar]
  7. Lai K. N., Ho C. P., Chan K. W., Yan K. W., Lai F. M., Vallance-Owen J. Nephrotic range proteinuria--a good predictive index of disease in IgA nephropathy? Q J Med. 1985 Oct;57(222):677–688. [PubMed] [Google Scholar]
  8. Lai K. N., Lai F. M., Chan K. W., Ho C. P., Leung A. C., Vallance-Owen J. An overlapping syndrome of IgA nephropathy and lipoid nephrosis. Am J Clin Pathol. 1986 Dec;86(6):716–723. doi: 10.1093/ajcp/86.6.716. [DOI] [PubMed] [Google Scholar]
  9. Lai K. N., Lai F. M., Ho C. P., Chan K. W. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol. 1986 Oct;26(4):174–180. [PubMed] [Google Scholar]
  10. Meyrier A., Simon P., Perret G., Condamin-Meyrier M. C. Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A. Br Med J (Clin Res Ed) 1986 Mar 22;292(6523):789–792. doi: 10.1136/bmj.292.6523.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nicholls K. M., Fairley K. F., Dowling J. P., Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med. 1984 Spring;53(210):227–250. [PubMed] [Google Scholar]
  12. Palestine A. G., Austin H. A., 3rd, Nussenblatt R. B. Renal tubular function in cyclosporine-treated patients. Am J Med. 1986 Sep;81(3):419–424. doi: 10.1016/0002-9343(86)90292-5. [DOI] [PubMed] [Google Scholar]
  13. Tipping P. G., Holdsworth S. R. Effect of cyclosporin A on antibody-induced experimental glomerulonephritis. Nephron. 1985;40(2):201–205. doi: 10.1159/000190341. [DOI] [PubMed] [Google Scholar]
  14. van Rijthoven A. W., Dijkmans B. A., Goei The H. S., Hermans J., Montnor-Beckers Z. L., Jacobs P. C., Cats A. Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum Dis. 1986 Sep;45(9):726–731. doi: 10.1136/ard.45.9.726. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES